Kornimate/medical-research-clean huggingface dataset:
effects of embryogen in rif patients

Conditions: Infertility

Summary: the purpose of this study was to investigate the potential effects of granulocyte-macrophage stimulating-colony factor (gm-csf) supplementation in embryo culture for patients with repeated implantation failure (rif)

60 patients with repeated implantation failure were involved. rif was defined as patients failed to conceive (beta-hcg \< 5 miu/ml) after at least 03 embryo transfers (fresh and frozen) with 06 top quality embryos or more. ovarian stimulation was performed using gnrh antagonist protocol. all matured oocytes were inseminated by icsi. injected oocytes were cultured in medium supplemented with 2ng/ml of gm-csf (embryogen, origio) until day of transfer. embryo evaluation was performed at ﬁxed time points of 18 and 44 hour after fertilization. embryo transfer was performed 2 days after ovum retrieval. luteal-phase support was provided using progesterone gel (crinone 8% 90 mg, twice a day; merck serono) and estradiol per os (valiera 2mg, twice a day; laboratorios recalcine). serum hcg was measured 16 days after oocyte retrieval, and if positive, an ultrasound scan was performed at gestational weeks 7 and 12.

Eligibility criteria:
inclusion criteria: * normal ovarian reserve (amh \> 1.1 ng/ml) * regular menstrual cycle (25 - 34 days) * clear informations about at least 3 latest ivf/et * fresh embryo transfer in this cycle * endometrial thickness of 10 mm or more exclusion criteria: * undergo oocyte donation or in vitro maturation (ivm) cycles * using frozen or surgically retrieved sperm * adenomyosis, uterine anomaly, uterine fibroid, hydrosalpinges * in participation in other studies/interventions

Keywords: gm-csf, repeated implantation failure
the value of early mobilization and physiotherapy following wrist fractures treated by volar plating

Conditions: Distal Radius Fracture; Wrist Fracture

Summary: a prospective, randomized study investigating the possible benefits of immediate mobilization and frequent physiotherapy following a wrist fracture treated by volar plating. the current study will test the following null hypothesis: there is no significant difference between patients who receive a cast for the first 2 weeks postoperatively and then instructions in home exercises and patients who receive a cast for 2-3 days postoperatively and then have frequent sessions with a physiotherapist following volar locked plating for a extraarticular distal radius fracture, as evaluated by self-reported satisfaction after 3 months.

the study will focus on patients treated with volar locked plating following an extraarticular distal radius fracture. in a prospective manner the investigators intend to analyze hand function, x-ray and other parameters in order to investigate whether early mobilization and a targeted program of physiotherapy postoperatively leads to a better functional result and earlier return to a normal activity level. the investigators analysis will also focus on the safety of early mobilization with regards to possible detrimental effects on the osteosynthesis, bony union, associated soft-tissue injuries and functional outcome. the investigators also intend to assess the cost of more intensive follow-up and physiotherapy and do a cost-benefit evaluation.

Eligibility criteria:
inclusion criteria: position prior to primary reduction: * dorsal tilt \> 25° * radial shortening\> 6 mm * radial inclination reduced by more than 15° * radiocarpal malalignment \> 7 mm * dorsal /volar metaphyseal comminution * volar displacement of the distal fragment(= smith's fracture) position after initial reduction: * dorsal tilt \> 5° * radial shortening \> 4 mm * radial inclination reduced by more than 10° * radiocarpal malalignment \> 4 mm exclusion criteria: 1. gustilo-anderson type iii open fractures 2. previous distal radius/ulna-fracture and/or disabling hand injury of the same extremity 3. previous distal radius fracture or other disabling injury to the contralateral side 4. dementia or other psychiatric illness which affect compliance 5. congenital anomaly 6. bilateral radius fracture 7. concurrent fractures to the upper or lower extremities or other illness which affect movement of the extremities 8. systemic joint disease such as rheumatoid arthritis 9. patients who do not speak norwegian 10. pathological fracture other than osteoporotic fracture 11. congenital bone disease (for example osteogenesis imperfecta) 12. age below 18 and above 70 13. patients not belonging to akershus university hospital

Keywords: distal radius fracture wrist fracture physiotherapy immobilization volar locking plates mobilization
intravenous ferric carboxymaltose (ferinject) in patients undergoing orthopaedic surgery

Conditions: Anemia; Orthopedic Surgery; High Risk of Blood Loss

Summary: the primary purpose of this study is to evaluate the safety and efficacy of preoperative intravenous ferric carboxymaltose in patients with anemia undergoing hip or knee replacement


Eligibility criteria:
inclusion criteria: * age \>= 18 years * patients scheduled to undergo hip or knee replacement * 8 g/dl \< hb \< 13 g/dl for men and 8 g/dl \< hb \< 12 g/dl for women at screening (3-4 weeks prior to surgery) * anemia * signed written informed consent exclusion criteria: * immunosuppressive or myelosuppressive therapy * history of thromboembolic events * a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient * hypersensitivity to any component of the formulation * transfusion within 1 month prior to study inclusion * liver values 3 times higher than normal * active severe infection/inflammation * renal insufficiency

Keywords: anemia transfusion intravenous ferric carboxymaltose
feasibility and evaluation of a self-care app to enhance purposeful living

Conditions: Ovarian Cancer

Summary: in this pilot study, ovarian cancer survivors will be enrolled and followed for six months to evaluate usage of an ehealth app called "purposeful".

this study will determine the feasibility and acceptability of purposeful, the ehealth app. first, feasibility of enrolling ovarian cancer survivors to use purposeful will be assessed. secondly, the acceptability of the app among ovarian cancer survivors will be assessed, based on frequency of use and validated acceptability measures. participants will be asked to complete other validated questionnaires so investigators may explore whether further research on the purposeful app among ovarian cancer survivors is warranted. this will include correlations between use of the purposeful app and the life purpose questionnaire score. lastly, correlation between life purpose and quality of life in ovarian cancer survivors will be explored.

Eligibility criteria:
inclusion criteria: * diagnosis of ovarian cancer or treatment for ovarian cancer through the university of michigan gynecologic oncology service * completed primary treatment (either surgery alone or surgery + chemotherapy) * ability to understand and the willingness to sign a written informed consent * ability to speak and read english exclusion criteria: * there are no additional exclusion criteria for participation in this study.
prospective randomized comparison of conservative and opertaive treatment of radius fractures in elderly patients

Conditions: Orthopedic Disorder

Summary: elderly patients often suffer from radius fracture. treatment options are conservative and operative. aim of the stdy is to find out if there are diffrences in patient's satisfaction depending on the different treatment. a randomized prospective trial is palnned

patients of 70 years and more of age who suffer from c1 or c2 radius fracture are randomized treated by conservative treatment and operative treatment. primary aim is prwe, secondary rom as well as power and dash score.

Eligibility criteria:
inclusion criteria: * radius fractures c1-c2 * age over 70 exclusion criteria: * demetia * collateral damages * age \< 70

Keywords: radius fracture, clinical outcome
biomarkers in hidradenitis suppurativa participants receiving brodalumab

Conditions: Hidradenitis Suppurativa

Summary: phase 0 study of brodalumab in patients with moderate to severe hidradenitis suppurativa to identify biomarkers of disease activity and clinical response.

phase 0, open label study of brodalumab in patients with moderate to severe hidradenitis suppurativa. consisting of n=10 patients receiving 210mg subcutaneously every 2 weeks for 24 weeks. patients will be followed for a period of 36 weeks (12 weeks after last dose of brodalumab) to assess for safety.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of hidradenitis suppurativa by the pi * age 18 or older * moderate to severe hidradenitis suppurativa as determined by the pi exclusion criteria: * inflammatory bowel disease * hiv positive * active hepatitis b or c infection * pregnant or breastfeeding * no concurrent use of any systemic antibiotics/retinoids/imunosuppressants (require washout period of \>5 half lives) * any medical, psychological or social condition that, in the opinion of the investigator, would jeopardize the health or well being go the participant during any study procedures or the integrity of the data * high suicide risk as determined by the columbia suicide severity rating scale * history of keloid scarring

Keywords: hidradenitis suppurativa acne inversa brodalumab
rifaximin plus lactulose versus lactulose alone for the treatment of hepatic encephalopathy: a double blind randomized trial

Conditions: Hepatic Encephalopathy

Summary: the study will be double blind with respect to rifaximin, and randomization will be performed using tables of computer-generated random numbers. all subjects will be followed up till the recovery of he (primary end point) or 10 days whichever is earlier. in the lactulose group (group a) patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day along with placebo . in the lactulose plus rifaximin group (group b) patients will receive cap rifaximin 400mg three times a day along with lactulose. primary endpoints will be recovery of overt he patients who will not recover from he after 10 days will be continued on the same treatment. total duration of the study is 1 year.


Eligibility criteria:
inclusion criteria: * cirrhosis * age 18-80 * hepatic encephalopathy grade ii-iv * informed consent exclusion criteria: 1. degenerative cns disease or major psychiatric illness 2. serum creatinine \> 1.5 mg/dl 3. active alcohol intake \<4 weeks prior to present episode 4. others metabolic encephalopathies 5. hepatocellular carcinoma 6. severe comorbidity such as chf, pulmonary disease, neurological \& psychiatric problems impairing quality of life
molecular characterization of neuroblastic tumor: correlation with clinical outcome

Conditions: Neuroblastoma

Summary: the purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. these research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.

to collect tumor, marrow specimens prospectively to study the molecular-genetic makeup of individual neuroblastic tumor and its metastasis by blood and marrow, and to correlate these findings with clinical outcome, and to relate the signaling circuitry of neuroblastic tumors to that of embryonic neuroectodermal cells. .

Eligibility criteria:
inclusion criteria: * neuroblastic tumors diagnosed in accordance with the international neuroblastoma staging system or * clinically suspected neuroblastic tumors. pk draw inclusion criteria (for pk draws only): pk draw inclusion criteria * patients who receive naxitamab as part of their standard of care exclusion criteria: * none

Keywords: adrenal gland no stage requirement
hla-mismatched microtransplantation without immunosuppressive treatment in patients with myeloid hemopathies

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes

Summary: this study aims at evaluating the safety of an approach based on hla-mismatched microtransplantation without immunosuppressive treatment in patients with myeloid hemopathies who are ineligible to conventional allograft


Eligibility criteria:
inclusion criteria: * age\> or = 65 years with a myeloid hemopathy in complete remission or complete remission with incomplete hematological recovery or age\<65 years with an ineligibility to allograft (contraindication to conditioning) * hla-partially matched family donors * affiliated to(or beneficiary of) the social security * informed consent signed exclusion criteria: * aml3 * previous hematopoietic stem cell transplantation * uncontrolled infection -ps\>3 -other progressive cancer * psychiatric disease * vulnerable person or unable to provide informed consent * emergency * unable to comply with required study follow up

Keywords: microtransplantation myeloid hemopathy
the time-restricted intake of meals study

Conditions: PreDiabetes; Obesity

Summary: trim is a randomized, controlled feeding study to evaluate if eating earlier in the day vs. later in the day impacts weight and glucose homeostasis.


Eligibility criteria:
inclusion criteria: * prediabetes defined by hba1c 5.7-6.4%, or type 2 diabetes with hba1c 6.5-6.9% * class i-iii obesity (bmi 30-50 kg/m2) * if on medications for hypertension, stable regimen for at least past 6 months * willingness to adjust timing of feeding * willingness and ability to eat study diet and nothing else during run-in and intervention * willingness to complete measurement procedures exclusion criteria: * moderate to severe obstructive sleep apnea * shift work; * other sleep/circadian disorders: e.g., circadian phase delay or phase advance; restless legs syndrome, insomnia, narcolepsy, habitual sleep \<6 hours/night * routinely ate within compressed time window in the past year (e.g., routinely eats all food within an 10-hour or narrower window, follows an intermittent fasting protocol) * renal dysfunction (estimated glomerular filtration rate (gfr) \<30 using the simplified chronic kidney disease (ckd) epidemiology collaboration (epi) equation 34) * use of glucose-lowering medications, weight loss medications, medications for sleep disorders (sedative/hypnotic drugs, stimulants), lithium, systemic corticosteroids, diuretics, blood thinners requiring regular monitoring (e.g. warfarin), anti-psychotic drugs and antiretroviral therapy * body weight \>400 pounds (limitation of facility scales) * \>1 drink per day of alcohol * active substance use disorder or significant psychiatric/psychologic disorder that would interfere with participation * significant food allergies, preferences, intolerances, or dietary supplements that would interfere with diet adherence * weight loss or gain of ≥5% during past 6 months * pregnant, planning to become pregnant, or breastfeeding * planning to start a weight loss program * planning to leave the area prior to end of study * current participation in another clinical trial * cancer diagnosis requiring active treatment in past two years or planned treatment (with exception of localized non-melanoma skin cancer) * active inflammatory bowel disease, malabsorption, or history of major gastrointestinal surgery involving bowel resection * myocardial infarction or stroke in past 6 months * prior bariatric surgery * any serious illness that would interfere with participation * other conditions or situations at the discretion of the pi
rotator cuff tears in hemiplegic shoulder

Conditions: Hemiplegia

Summary: the purpose of the study is to evaluate the prevalence of rotator cuff tears in the shoulders of hemiplegic patients of different severity.

rotator cuff tears are often suspected to contribute hemiplegic shoulder pain. however, it is controversial whether their incidence increases in hemiplegia. based on the postulate that muscle weakness in hemiplegia predisposes rotator cuff injury due to biomechanical failure, this study aims to investigate whether the rotator cuff tears are associated with the muscle strength of the shoulder by observing hemiplegic shoulders of varying degree of paresis.

Eligibility criteria:
inclusion criteria: * hemiplegia; unilateral weakness of sudden onset * secondary to strokes or other brain lesions * compatible with brain lesions confirmed by imaging studies exclusion criteria: * bilateral weakness * any history of intensive trauma of the shoulder, reported * preexisting musculoskeletal disorder of the shoulder

Keywords: rotator cuff tendinopathy ultrasonography
role of uterotonics in reducing intraoperative blood loss in patients with pasd undergoing cesarean hysterectomy

Conditions: Placenta Accreta Spectrum

Summary: objectives: to evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with pas disorders planned for cesarean hysterectomy.


Eligibility criteria:
inclusion criteria: * pregnancy of singleton living fetus * previous one or more cesarean sections * gestational age: \> 32 weeks * the following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity". * preoperative hemoglobin more than 10 gm/dl * cases with pas that will undergoing cs hysterectomy exclusion criteria: * maternal medical disorders e.g.: coagulation defects, cardiac diseases etc..... * any known or reported hypersensitivity to the used medication. * all cases with spontaneous placental separation at laparotomy. * all patients undergoing conservative management of pas. * all cases which necessitate emergency termination.
miltefosine (long course) for bolivian mucosal leishmaniasis

Conditions: Leishmaniasis

Summary: miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi

Eligibility criteria:
inclusion criteria: * mucosal leishmaniasis exclusion criteria: * no comcomitant disease as judged by laboratory and clinical parameters

Keywords: mucosal miltefosine
a multi-center, randomized, double-blind phase iii clinical trial to assess and compare to the efficacy and safety of lafutidine, famotidine and omeprazole-referenced in korean erosive esophagitis patients

Conditions: Erosive Esophagitis

Summary: to evaluate the healing rate and safety of lafutidine in erosive esophagitis


Eligibility criteria:
inclusion criteria: * patients who had symptoms of heartburn with a diagnosis of grade a to d reflux esophagitis according to the los angeles classification exclusion criteria: * gastric or duodenal ulcers (excluding ulcer scars) * concurrent presence of barrett's esophagus * a history of a poor response to h2ra or ppi given in the recommended dose for 8 weeks * other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety
phase i/ii study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk myelodysplastic syndrome (mds) or acute myeloid leukemia (aml)

Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia

Summary: the study's primary objective is to determine the maximum tolerated dose (mtd) and dose-limiting toxicity (dlt) of panobinostat when administered within 150 days after hematopoietic stem cell transplantation (hsct) and given in conjunction with standard immunosuppressive therapy after hsct for patients with high-risk myelodysplastic syndrome (mds) or acute myeloid leukemia (aml). secondary objectives are * to determine safety and tolerability of panobinostat * to determine overall and disease-free survival at 12 months after hsct * to evaluate immunoregulatory properties of panobinostat * to evaluate patient-reported health-related quality of life (hrql) the hypothesis of this study is that panobinostat can be an effective drug in preventing relapse of mds and aml patients with high-risk features after hematopoietic stem cell transplantation with reduced-intensity conditioning (ric-hsct) while at the same time reducing graft-versus-host disease (gvhd) with preservation of graft-versus-leukemia (gvl) effect.


Eligibility criteria:
inclusion criteria: * aml (except acute promyelocytic leukemia, aml m3) with high-risk features defined as one or more of the following criteria: * refractory to or relapsed after at least one cycle of standard chemotherapy * \> 10% bone marrow blasts at day 15 of the first induction cycle * adverse risk cytogenetics including complex karyotype (≥ 3 abnormalities or abnormalities of chromosomes 3, 5 or 7) regardless of stage * secondary to mds or radio-/chemotherapy or * mds raeb according to the who classification or intermediate-2 or high-risk according to ipss or * chronic myelomonocytic leukemia (cmml) with ≥ 5% bone marrow blasts and * allogeneic hsct with reduced intensity conditioning (see section 15.1 for definition) performed within 60 - 150 days prior to study entry * complete hematologic remission documented by bone marrow aspiration within 28 days prior to study entry exclusion criteria: * active acute gvhd overall grade 2 - 4 * prior treatment with a deacetylase (dac) inhibitor * patients with impaired cardiac function or other concurrent severe and/or uncontrolled medical conditions * clinical symptoms suggesting central nervous system (cns) leukemia * patient has an impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of oral panobinostat

Keywords: 60 to 150 days after allogeneic stem cell transplantation high risk mds mds aml
study to evaluate the effect of alna® (tamsulosin) on the primary symptoms of benign prostatic hyperplasia

Conditions: Prostatic Hyperplasia

Summary: the aims of this observational study are to identify the primary bph symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of alna®, to assess the clincial efficacy on an improved occupational performance of the patients being still employed. additionally to obtain relevant information for the 5-year report of experience with this product according to the requirements in § 49, para 6 of the german medicines act.


Eligibility criteria:
inclusion criteria: * patients suffering from symptomatic benign prostatic hyperplasia (bph) symptoms and receiving alna® treatment are to be included in the observation according to the prescribing information exclusion criteria: no exclusion criteria is defined, prescribing information is to be considered
a study of 18f-alf-nota-octreotide pet/ct for imaging neuroendocrine neoplasms

Conditions: Neuroendocrine Neoplasm

Summary: the aim of this study is to investigate the clinical value of \[18f\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18f-alf-nota-octreotide ） positron emission tomography / computed tomography (pet/ct) in patients with neuroendocrine neoplasms (nens).

18f-alf-nota-octreotide is a radioligand targeting the somatostatin receptor, which is widely expressed on the cell surface of nens. the radioligand can be used for the diagnosis and stage of the nens. a total of 5 volunteers and 60 nen patients will be subjected to a 18f-alf-nota-octreotide pet/ct scan. the uptake of 18f-alf-nota-octreotide in organs and tumor lesions will be quantified as standardized uptake values (suvmax/suvmean).

Eligibility criteria:
inclusion criteria: 1. histologically and/or clinically confirmed and/or suspicious of nen. 2. signed informed consent. exclusion criteria: 1. claustrophobia (unable to accept pet/ct scanning) 2. pregnant or breast-feeding

Keywords: 18f-alf-nota-octreotide